Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2. A case report

Cancer
H M Fathallah-ShaykhD H Unwin

Abstract

Primary leptomeningeal melanomas are rare tumors that originate in the leptomeninges and are associated with a poor prognosis and no response to radiation and chemotherapy. These tumors rarely metastasize outside the central nervous system. Recombinant interleukin-2-(rIL-2) is a cytokine that activates natural killer cells and lymphokine-activated killer cells, augments their antitumor effects, and recruits and activates cytotoxic T lymphocytes. We have hypothesized that rIL-2 may prolong disease free survival in a patient with primary leptomeningeal melanoma. The patient was treated with intrathecal rIL-2 via lumbar puncture daily for 5 days, the weekly for 5 weeks. To investigate whether rIL-2 induced a favorable clinical response, the following parameters were monitored: survival, neurologic status, cerebrospinal fluid (CSF) analysis, visual fields, and magnetic resonance imaging (MRI) of the lumbosacral spine. The patient is still alive and disease free 15 months after receiving rIL-2, and his neurologic status remains unchanged. The CFS glucose concentration, undetectable prior to therapy, has become normal. Repeated cytologic examinations of CSF were negative for malignant cells. The visual field examinations have remaine...Continue Reading

References

Jan 1, 1991·Medical and Pediatric Oncology·L MeisterB Arendash-Durand
Feb 1, 1974·Archives of Neurology·J R LittleH Okazaki
Nov 1, 1972·Archives of Ophthalmology·P A AltrocchiP B Eckman
Mar 23, 1994·JAMA : the Journal of the American Medical Association·S A RosenbergD E White
Jan 1, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·W E SamlowskiG B Schumann
Feb 11, 1956·British Medical Journal·K W HEATHFIELD, J R WILLIAMS
Jul 1, 1965·Annals of Internal Medicine·Y S KIM, J S RESNICK
Jan 1, 1955·Brain : a Journal of Neurology·M FISCHER-WILLIAMSP M DANIEL
Nov 1, 1961·American Journal of Ophthalmology·J L KATZR S JAMPEL

❮ Previous
Next ❯

Citations

Nov 15, 2008·Journal of Pharmaceutical Sciences·Mohamed A Shaker, Husam M Younes
Jun 19, 2010·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Simon V LiubinasKatharine J Drummond
Oct 26, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·D NashanA Enk
Apr 15, 2003·Neurologic Clinics·Santosh Kesari, Tracy T Batchelor
Feb 20, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicole A ShonkaMichele R Aizenberg
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kim KramerNai-Kong V Cheung
Jan 24, 2017·The Cancer Journal·Isabella Glitza OlivaMichael A Davies
Jan 10, 2020·Pigment Cell & Melanoma Research·Isabella C GlitzaPeter Forsyth
Dec 18, 2002·Spine·Frank Schneider, Michael Putzier
May 23, 2017·Therapeutic Advances in Medical Oncology·Tresa McGranahanSeema Nagpal
Mar 9, 2019·Journal of Neuro-oncology·Sherise D FergusonIsabella C Glitza

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.